OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

Even More CPTAC Pathology Images Available!

...And there's more!!!  Another new batch of CPTAC histopathology imaging data has been released and is now publicly available on the TCIA CPTAC Pathology Portal.


CPTAC Researchers Associate High Immune Checkpoint Components and Immune Tolerance with Poor Clinical Outcomes in Luminal B Breast Cancer

As part of NIH’s mission for collaboration and team science, Dr. Matthew Ellis, Co-Principal Investigator of the CPTAC Proteogenomic Translational Research Center and Dr.


OCCPR Webinar: Proteomic Assay Portal

Did you know about NCI’s Proteomic (CPTAC) Assay Portal?  It’s a free resource for biological scientists performing mass spectroscopy.  The portal houses more than 2300 fit-for-purpose, proteomic assays designed and optimized for anyone to use.   Each assay is validated using CPTAC experimental g


The CPTAC Pathology Portal Has New Images

A new batch of CPTAC histopathology imaging data has been released and is now publicly available on the TCIA CPTAC Pathology Portal.

The TCIA quarterly report lists the addition of 76 new pathology slides and 25 new pathology subjects for the cutaneous melanoma, glioblastoma multiforme, and sarcoma tumor types.

TCIA has partnered with CPTAC to host both the radiology and pathology imaging data generated by the CPTAC Program.  Imaging data is available for 10 cancer types including AML, clear cell renal cell carcinoma, head & neck squamous cell carcinoma, lung squamous...


GDC Releases Harmonized Genomic Data From CPTAC

Data Release-20 from the Genomic Data Commons (GDC) includes genomics from a new CPTAC project!  

The CPTAC Proteogenomic Confirmatory Study examined prospectively collected colon, breast and ovarian tumors for analysis, including harmonized whole exome sequencing, RNA-Seq, and miRNA-Seq that is now available.  Complimentary proteomic and phosphoproteomic analysis can also be found on the CPTAC Data Portal and the Proteomic Data Commons (PDC).

CPTAC has provided the Genomic Data Commons (GDC) with genomic data from over 600 cancer patients with diverse disease types including...


CPTAC Researchers Reveal Novel Biological Features of Kidney Clear Cell Carcinoma

Investigators with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) have generated the most comprehensive multi-omics dataset for clear cell renal cell carcinoma (ccRCC), the most commonly diagnosed kidney cancer subtype. The investigators used integrative proteogenomics, to reveal new insights into kidney cancer.


CPTAC Scientific Symposium 2019 – Great Beginnings!

Over three hundred proteomic explorers and  Clinical Proteomics Tumor Analysis Consortium (CPTAC) participants from around the country convened on the NIH Bethesda campus to share cutting-edge proteogenomic research in the first ever, public-facing CPTAC Scientific Symposium.


One Computational Step in the Journey to Identify Biological Pathways in Cancer

Large multi-omics datasets are becoming increasingly popular for studying biological systems including the identification of biological pathways, or more broadly defined gene sets, that are associated with certain biological or clinical features of interest.


ICPC China Team Comprehensively Characterizes HBV Related Liver Cancer

Hepatocellular carcinoma (HCC), the most common form of liver cancer, occurs most often in people with hepatitis B or C viral (HBV or HCV) infections who drink large amounts of alcohol.  Unlike the recent progress of antiviral-eliminating therapy for HCV, current antiviral therapy is only able to reduce rather than eliminate HBV and is estimated to affect 292 million peop


Pages